Bristol-Myers Squibb EV/EBIT BMY

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2010.

Today, Oct 23, 2026: 12.4×
10-year median: 16.3×
Against its 10-year history: 9th; percentile: 0 is its lowest day, 100 its highest
10-year range: 8.8× to 55.8×
Peer median: 24.0×

Bristol-Myers Squibb's EV/EBIT is 12.4× as of Oct 23, 2026.

That is below its ten-year median of 16.3×, lower than on 91% of days in the last ten years.

Over that time it ranged from 8.8× in Jul 2019 to 55.8× in Aug 2020.

The median for 9 large drugmakers of a similar size is 24.0×.

EV/EBIT over time

median 16.3×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	12.4×	12.0×	16.6×
2025	15.0×	13.2×	17.9×
2024	13.6×	12.4×	14.7×
2023	12.9×	12.6×	17.8×
2022	17.3×	17.3×	22.1×
2021	33.3×	33.3×	35.9×
2020	33.8×	15.0×	55.8×
2019	15.4×	8.8×	15.8×
2018	15.5×	15.2×	24.0×
2017	19.6×	14.8×	20.2×
2016	19.7×	17.2×	47.0×
2015	43.3×	33.8×	49.9×
2014	33.8×	17.4×	34.8×
2013	18.5×	11.4×	18.6×
2012	12.9×	7.9×	13.5×
2011	9.0×	6.7×	9.0×
2010	7.8×	6.9×	8.3×

Against its peers

Companies in Drug Manufacturers - General nearest Bristol-Myers Squibb's size, closest first, today.

Company	EV/EBIT
BMYBristol-Myers Squibb	12.4×
PFEPfizer	14.5×
GILDGilead Sciences	23.4×
AMGNAmgen	24.6×
MRKMerck	20.4×
BIIBBiogen	26.3×
ABBVAbbVie	27.2×
JNJJohnson & Johnson	n/m
JAZZJazz Pharmaceuticals	15.9×
LLYEli Lilly and	35.7×
Peer median	24.0×

Where Bristol-Myers Squibb ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Bristol-Myers Squibb

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.